Publications by authors named "Ilonka H P A A van Veen"
Pulmonary thromboembolism (PTE) is a common complication in coronavirus disease 2019 (COVID-19) patients. Elevated D-dimer levels are observed even in the absence of PTE, reducing its discriminative ability as a screening test. It is unknown whether conventional D-dimer cut-off values, as used in the YEARS algorithm, apply to COVID-19 patients.
View Article and Find Full Text PDFArticle Synopsis
- Bronchiectasis is a common issue in severe eosinophilic asthma patients, impacting disease severity, but its effect on IL-5 biologic treatment is unclear.
- A study of 97 adults showed that anti-IL-5/5Ra therapy significantly reduced asthma exacerbations and the need for oral corticosteroids (OCS).
- After one year of treatment, exacerbation rates dropped from 74.5% to 22.1%, and the number of patients on maintenance OCS decreased from 47% to 30%, highlighting the therapy's effectiveness even in those with bronchiectasis.
Background: Reslizumab, a biologic targeting IL-5, has been shown to reduce asthma exacerbations and maintenance oral corticosteroid use in randomized controlled trials and pre-post studies in patients with severe eosinophilic asthma. However, real-world effectiveness data of reslizumab are scarce, and it is unknown whether reslizumab has added value after switching from another type 2 biologic.
Objective: To evaluate (1) the real-world effectiveness of reslizumab on severe asthma exacerbations, maintenance oral corticosteroid use, and overall treatment response, both in biologic-naive patients who initiated reslizumab and in those who switched from another type 2 biologic; and (2) physicians' experience with reslizumab treatment.
A 37-year-old woman presented with a 2-month history of recurrent hemoptysis and coughing. Her symptoms started 2 months after the delivery of her third child. In total, she endured four episodes of hemoptysis.
View Article and Find Full Text PDF